| Formal Name: | Pharmaceutical and Therapeutics Committee |
| Contact Person: | Nicole Barrett |
| Purpose: | See authorizing statute. |
| How Many Affectable: | blank |
| How Many Served: | blank |
| Year Created: | blank |
| Year Active: | blank |
| Sunset Date: | blank |
| Authorization Citation: | Neb. Rev. Stat. 68-953 |
| Parent Agency: | Department of Health and Human Services |
| Number Of Members: | Fifteen current members, no more than twenty allowed |
| Who Appoints: | The Director of the Division of Medicaid & Long-Term Care |
| Legislative Approval: | No |
| Qualifications Of Members: | The committee shall consist of eight physicians, four pharmacists, a university professor of pharmacy or a person with a doctoral degree in pharmacology, and two public members. No more than twenty-five percent of the committee shall be state employees. The physician members of the committee (as practicable) shall include physicians in the practicing areas of family medicine, internal medicine, pediatrics, cardiology, psychiatry or neurology, obstetrics or gynecology, endocrinology, and oncology. |
| Per Diem: | No |
| Expense Reimbursement: | Yes |
| Term Length: | Three years, with additional reappointments for three years |
| Terms Rotate or Expire At Once: | Terms Rotate |
| Required FY 21-22: | 2 |
| Held FY 21-22: | 2 |
| Required FY 22-23: | 2 |
| Held FY 22-23: | 2 |
| Required FY 23-24: | 2 |
| Held FY 23-24: | 2 |
| Support Staff: | Three to four MLTC Pharmacy staff and contracted vendor |
| Shared or Separate: | Separate |
| FY 21-22 Budget: | 0 |
| FY 22-23 Budget: | 0 |
| FY 23-24 Budget: | 0 |
| Other Funding Sources: | General and Federal Funds |
| Spending Authority: | Spending authority for the Fund is established each biennium in the budget bill. |
| Since July 1, 2020: | These accomplishments are provided by the Department of Health and Human Services and reflects its sole views. The Committee has successfully reviewed drug classes that are included in the preferred drug list (PDL) and split them into two groups of classes, one group is reviewed at each meeting. The PDL decisions by the Committee have significant savings on drugs for MLTC as well as providing sound judgement for coverage of medications in the most safe and efficacious manner. |